Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Terremoto Biosciences has raised $108.0M in total funding. The most recent round was Series C. The last funding was announced in April 2026.
Terremoto Biosciences's investors include RA Capital Management, Cormorant Asset Management, Novo Holdings, OrbiMed, OUP (Osage University Partners).
Terremoto Biosciences is headquartered in San Francisco, United States.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Terremoto Biosciences is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Terremoto Biosciences — Funding & Investors." VCBacked, April 15, 2026, https://www.vcbacked.co/company/terremoto-biosciences. Accessed July 19, 2026.
VCBacked. (2026). Terremoto Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/terremoto-biosciences
{{cite web |title=Terremoto Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/terremoto-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated